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Abstract
Background: Homocysteine is considered to be a risk factor, or an indicator of risk, for the
development of cardiovascular disease. Little data is available on its significance in patients
with previous myocardial infarction. The aim of our study was to assess the plasma level of
homocysteine and its relationship with the severity of heart failure in patients with chronic
myocardial infarction.
Methods: We studied 144 patients with previous myocardial infarction. Patients were
divided into two groups according to the presence or absence of heart failure, as certified by
clinical evidence of heart failure and by echocardiographic criteria for left ventricular systolic
dysfunction.
Results: Of the patients with prior myocardial infarction (144; 63.6 ± 9.6 years) included
in the study, 65 had heart failure. The mean level of homocysteine was significantly higher in
the heart failure group (18.9 mmol/L) than in the non-heart failure group (14.1 mmol/L;
p £ 0.001). Our study demonstrated that there is a statistically significant correlation
between homocysteine plasma levels and the severity of heart failure in patients with prior
myocardial infarction. Homocysteine levels have proved to become higher with NYHA class
progression. A significant cross-sectional correlation has been assessed between homocysteine
and tissue Doppler echocardiography parameters.
Conclusions: Increased plasma homocysteine levels independently correlate with the severity
of heart failure in patients with chronic myocardial infarction. We suggest that homocysteine
can be used in clinical practice as a valuable heart failure risk marker in patients with
chronic myocardial infarction. (Cardiol J 2011; 18, 1: 55–62)
Key words: homocysteine, myocardial infarction, left ventricular dysfunction,
heart failure
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Introduction
Myocardial infarction (MI) is an important fac-
tor in the occurrence of heart failure (HF) [1]. Its
association with other risk factors, such as left ven-
tricular hypertrophy (LVH), valvular heart disease,
hypertension, diabetes mellitus, cigarette smoking,
obesity, and dyslipidemia [2], doubles or trebles the
risk of HF development [3].
Recently, the elevation of plasma homocys-
teine (Hcy) level has been recognised as a risk fac-
tor for HF [4, 5]. In experimental models, hyper-
homocysteinemia has been shown to induce LVH
and cardiac fibrosis which determine systolic and
diastolic dysfunction, as well as increase brain natri-
uretic peptide (BNP) expression [6].
Theoretically, elevated Hcy levels could pro-
mote HF by several mechanisms: stimulation of
collagen production by vascular smooth muscle cells
and inhibition of endothelial cell growth; promotion
of oxidative stress; stimulation of matrix metallo-
proteinase production which promotes endothelial
dysfunction; or reduction of vasodilator capacity,
ultimately leading to atherosclerosis [7].
In humans, a moderately increased plasma le-
vel of Hcy and genetic factors associated with en-
zymatic abnormalities of folic acid and Hcy metab-
olism play a major role in the development of coro-
nary heart disease (CHD) and hence of HF [8].
The normal concentration of plasma Hcy ran-
ges between 5 and 15 µmol/L; elevations of plasma
Hcy from 15 to 30 µmol/L, 30 to 100 µmol/L and
> 100 µmol/L are classified as mild/moderate, in-
termediate and severe hyperhomocysteinemia, re-
spectively [9].
Prospective data in high-risk patients has sug-
gested that mild or moderate hyperhomocysteine-
mia [10] could be a risk factor for recurrent cardio-
vascular events and overall mortality [11].
Patients with previous MI are at risk of devel-
oping HF. Although the incidence of HF after MI
has diminished in recent decades, it remains a com-
mon complication which occurs in up to 45% of cas-
es. Moreover, up to 60% of MI will result in LV sys-
tolic dysfunction, depending on the exact definition
used [12].
Our study aims to determine whether the pres-
ence of HF is associated with elevated levels of
Hcy > 15 µmol/L and to determine the relationship




We studied 144 consecutive patients with pre-
vious MI. This study was conducted according to
the Helsinki Declaration on Studies on Humans and
approved by the local ethics committee.
Only patients with a history of MI within the
last three months, as defined by international cri-
teria, were included in our study.
The main exclusion criteria were: major events
during hospitalization (i.e. neoplasia, inflammatory
diseases, infections, hypotension, shock, and renal
impairment); ongoing clinical instability (such as
angina or arrhythmia); surgical interventions in the
last two months or subsequent dyslipidemia as
a result of hypothyroidism, nephrotic syndrome or
cholestasis.
Patients were divided into two groups accord-
ing to their LV systolic function and clinical evidence
of HF according to the New York Heart Associa-
tion (NYHA) classification criteria: Group 1 (the
study group) included patients with reduced LV
ejection fraction (LVEF) £ 40% and clinical evi-
dence of HF; Group 2 (the control group) consist-
ed of patients with LVEF > 40% in which no clini-
cal evidence of HF had been identified.
Echocardiography variables
All patients were studied by conventional and
tissue Doppler echocardiography using a Hewlett-
-Packard Sonos 5500, Philips, ultrasound system,
using a 2.5 MHz wide-angle phased-array transduc-
er. Recordings were made via simultaneous super-
imposed electrocardiography.
Conventional echocardiography 2D-, M-mode
and Doppler was used for each patient. Tracings
from the parasternal long axis view were used to
measure septal thickness, LV diameter at end-di-
astole and end-systole, and posterior wall thickness.
LVEF was derived from Simpson’s modified single
plane method using the apical four-chamber view
[13]. We considered LVEF < 40% to be an accu-
rate marker for LV systolic dysfunction.
Comprehensive assessment of LV diastolic
function included transmitral pulsed wave Doppler
from an apical four-chamber view. From the trans-
mitral flow, the peak early (E) and late atrial (A)
diastolic velocities, E-deceleration time (DT) and
isovolumetric relaxation time were successfully
recorded for all patients. Normal diastolic function
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was defined as an E/A ratio of 1–1.5 and a DT of
160–230 ms. The classification of diastolic dysfunc-
tion according to echocardiographic criteria includ-
ed the following categories: 1) abnormal relaxation
pattern; 2) pseudonormal pattern; and 3) restrictive
pattern. Impaired LV relaxation was defined as
E/A < 1 and E-DT > 230 ms, while the pseudonor-
mal pattern was defined as E/A of 1.5–2 and an E-DT
< 230 ms. The restrictive pattern is defined by the
combination of E/A > 2 and an E-DT < 160 ms.
Tissue Doppler echocardiography was used to
assess LV longitudinal myocardial wall motion from
the apical four-chamber view [14]. A sample volume
of 2 mm was used, with the frame rate exceeding
100 m/s placed at the junction of the LV wall with
the mitral annulus on the lateral myocardial seg-
ments. Peak systolic myocardial velocity during
ejection (Sm), early (Em) and late (Am) diastolic
velocities were measured by pulsed wave tissue
Doppler imaging. The transducer was positioned to
align the ultrasound beam with longitudinal LV
motion. The ratio of E to lateral Em was used to
estimate LV filling pressures. Normal diastolic func-
tion was defined as E/Em of < 8 and the impaired
LV filling pressure was defined as E/Em of > 8 [14].
Blood sampling and biochemical testing
Venous blood samples were obtained after
12 hours of fasting; for measuring lipids, creatinine,
Hcy and BNP, blood samples were drawn without
stasis into evacuated glass tubes containing 1/100
volume of 0.5 mmol of ethylene diamine tetra acetic
acid/L. Plasma was obtained by centrifugation at 1,500
g for 15 min and was measured in fresh samples.
The fasting Hcy levels were measured in all pa-
tients using fluorescence polarization immunoassay
on Abbott Imx Analyzer [15]. In our study, normal
Hcy levels range between 5 and 15 µmol/L, with
elevations of 15 to 30 µmol/L, 30 to 100 µmol/L and
> 100 µmol/L being classified as mild, moderate,
and severe hyperhomocysteinemia, respectively.
Plasma BNP was measured via commercial Triage
assay (Biosite Diagnostics, Inc., San Diego, CA, USA)
[16]. Plasma levels of total cholesterol (TC), HDL-
-cholesterol (HDL-C), LDL-cholesterol (LDL-C),
and triglycerides (TG) were measured in all patients
using enzymatic tests performed by a Roche-Hita-
chi 911 analyzer [17].
Other clinical variables
We recorded the presence of several risk fac-
tors, such as: age, sex, family history of CHD, smok-
ing, hypertension, diabetes mellitus, obesity and
dyslipidemia in accordance with international criteria.
Family history of CHD was defined as a history of
premature coronary artery disease in first-degree
relatives (having occurred in those relatives at age
< 55 for men and < 65 for women). Subjects who had
smoked at least one cigarette per day over the previ-
ous two months were considered active smokers.
The presence of hypertension at baseline was
defined as systolic blood pressure > 140 mm Hg,
diastolic blood pressure > 90 mm Hg or use of an-
tihypertensive drugs, according to the current de-
finition. The presence of diabetes at baseline was
defined as fasting plasma glucose > 126 mg/dL
(7 mmol/L) or use of oral hypoglycemic agents or in-
sulin. A surrogate marker for obesity content is body
mass index (BMI), which is calculated as the weight
(kg) divided by height squared (m2). In clinical terms,
a BMI of 25–29 kg/m² corresponds to overweight,
whereas 30 kg/m2 plus corresponds to obesity.
Statistical analysis
A commercially available statistical program,
Statistical Package of Social Sciences (SPSS 13.0,
Chicago, IL, USA) and Medcalc 8.3.1.1.were used.
All data is presented as mean and standard devia-
tion (SD). The c2 or Fisher tests were used (accord-
ing to standard application criteria) for univariate
qualitative data analyses to assess the differences
between the group with LV diastolic dysfunction
and the group without LV diastolic dysfunction.
Continuous data were analyzed using the t Student
test for independent samples or Mann and Whitney
U test, according to the normality of data. Multivari-
ate analyses were performed by means of logistic
regression. The results were considered statistical-
ly significant for a p value < 0.05.
Results
Patients’ characteristics
In our study the mean age was 63.6 ± 9.6 years;
the group comprised males and females in similar
proportions; 51 (35.4%) cases presented with diabe-
tes mellitus, 122 (84.7%) were recorded as having
hypertension and 87 (55.5%) patients were smok-
ers. Family history of CHD was present in 36 (25.0%)
patients, while obesity was recorded in 74 (51.4%)
cases. Prevalence of HF in this series was 45.1%
(65 patients, 30 males and 35 females). The group
without HF comprised 79 (54.8%) patients (Table 1).
Echocardiographic characteristics
Of the 65 patients with HF, 17 (26.1%) present-
ed with normal diastolic function, 38 (58.5%) had an
altered relaxation pattern and ten (15.4%) patients
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had a pseudonormal pattern. There were no patients
with restrictive pattern in our study group. There
were no significant differences between the two
groups regarding diastolic function estimated by the
transmittal flow velocity variables. LV parameters
evaluated by echocardiography in the two groups are
shown in Table 2. Regarding the diastolic tissue
Doppler parameters, significant differences between
the two groups were obtained (Table 2).
Association of homocysteine levels
with heart failure
Higher levels of Hcy were found in the study
group (Group 1: the low LVEF group, with HF) than
in the control (Group 2: without HF). The differ-
ence in levels was statistically significant: 18.9
(10.0) vs 14.1 (5.2); p = 0.001.
During follow-up, hyperhomocysteinemia
> 15 mmol/L was found in 39.9% (26/65) of patients
with HF vs 27.3% (22/79) of patients without HF
(p = 0.01).
The multivariate model included cardiovascu-
lar risk factors (diabetes, hypertension, smoking,
BMI, TC, TG, HDL-C), Hcy, BNP and creatinine
(Table 3) and showed significant predictive values
for Hcy (p = 0.001), HDL-C (p = 0.035) and BNP
(p = 0.042). The association between elevated Hcy
and HF remained significant after adjusting for tra-
ditional cardiovascular risk factors (Model 1). Fur-
ther adjustment for LVEF or LV mass index still
returned statistically significant values (Model 2).
However, the association between Hcy and HF was
no longer significant after adjusting for the presence
of diastolic dysfunction estimated by the transmit-
tal flow velocity variables. Despite that, the asso-
ciation between Hcy levels and diastolic impairment
evaluated by tissue Doppler still proved to be sig-
nificant (Model 3). The association between
elevated Hcy and HF remained significant after
adjusting for creatinine level (Model 4).
Relationship between homocysteine levels
and severity of heart failure
Hcy values elevated stepwise with increasing
NYHA class (controls: 16.8 ± 5.2 µmol/L, NYHA I:
18.3 ± 4.9 µmol/L, NYHA II: 22.7 ± 6.8 µmol/L,
NYHA III+IV: 25.2 ± 5.4 µmol/L and correlation
analyses (including patients and controls) revealed
a significant relation between Hcy and NYHA class
severity of HF (p = 0.001, Fig. 1).
Table 1. Results of univariate and multivariate analyses of possible risk factors of heart failure after
myocardial infarction.
Univariate analyses Multivariate analyses
Variables Patients Patients P OR (95%CI) P
without HF with HF
(n = 79) (n = 65)
Age (years) 63.4 (9.9%) 64.1 (9.2%) 0.651
Gender (men/women) 42/37 30/35 0.402
Systolic blood pressure [mm Hg] 145.5 (24.7%) 159.6 (26.2%) 0.001
Hypertension 62 (68.8%) 60 (92.1%) 0.001 1.8 (0.7–3.1) 0.189
Diabetes mellitus 13 (16.5%) 38 (58.5%) 0.001
Smoking status 34 (43.0%) 53 (81.5%) 0.001 1.2 (0.7–1.5) 0.246
Family history of CHD 20 (25.3%) 19 (29.2%) 0.913
Obesity 34 (43.0%) 40 (61.5%) 0.027
Waist circumference [cm] 98.9 (13.2%) 108.4 (12.3%) 0.001 1.9 (0.8–2.9) 0.134
Body mass index [kg/m2] 28.1 (6.7%) 32.4 (5.3%) 0.027 1.7 (0.8–2.1) 0.318
Homocysteine [µmol/L] 14.1 (5.2%) 18.9 (10.0%) 0.004 2.05 (1.5–2.5) 0.001
Total cholesterol level [mg/dL] 169.6 (51.2%) 191.4 (45.0%) 0.008 2.1 (0.9–2.4) 0.267
Triglycerides level [mg/dL] 116.1 (57.7%) 147.5 (68.8%) 0.003 2.4 (0.8–3.1) 0.189
HDL-cholesterol level [mg/dL] 44.4 (10.1%) 34.7 (14.7%) 0.001 0.7 (0.3–0.9) 0.035
LDL-cholesterol level [mg/dL] 111.5 (44.6%) 124.4 (40.8%) 0.074
BNP [ng/L] 143 (49.7%) 382 (37.9%) 0.001 2.3 (0.4–4.2) 0.042
Creatinine [mmol/L] 85 (0.16%) 93 (0.17%) 0.038
Logistic regression analyses model included: diabetes, hypertension, smoking, body mass index, total cholesterol, triglicerydes, HDL-C, homocyste-
ine, creatinine; HF — heart failure; CHD — coronary heart disease; BNP — brain natriuretic peptide; OR — odds ratio; CI — confidence interval
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Analyses also revealed a significant correlation
between Hcy levels and HF severity, either as-
sessed by NYHA IV class (p = 0.007), BNP value
or quantified by echocardiographic parameters:
LVEF (p = 0.023), mitral E/A ratio (p = 0.002) or
mitral E/Em ratio (p = 0.043). Univariate results
are presented in Table 4.
Discussion
Several recent studies have shown that the
elevation of plasma Hcy levels may be an indepen-
dent risk factor for HF. Hcy seems to induce LVH
and cardiac fibrosis which can lead to systolic and
diastolic dysfunction, clinically expressed by a sig-
nificant increase in BNP plasma levels. Our results
suggest that the risk for developing HF in patients
with previous MI and low LVEF increases with el-
evated Hcy levels. A significant cross-sectional cor-
relation has been assessed between Hcy and tissue
Doppler echocardiography parameters, such as E/Em
ratio calculated at the level of the LV lateral wall.
Table 2. Left ventricular (LV) parameters by conventional and tissue Doppler echocardiography of groups.
Parameters Patients without HF Patients with HF P
(n = 79) (n = 65)
End-diastolic ventricular septal thickness [cm] 11.9 ± 1.5 12.2 ± 1.8 0.467
End-diastolic LV posterior wall thickness [cm] 12.7 ± 1.3 11.8 ± 2.0 0.332
End-diastolic LV diameter [cm] 48.9 ± 3.7 52.2 ± 4.1 0.186
End-systolic LV diameter [cm] 33.9 ± 2.1 39.4 ± 2.5 0.385
LV ejection fraction (%) 51.4 ± 8.7 38.3 ± 7.6 0.047
LV mass index [g/m²] 95.7 ± 14.1 99.9 ± 19.2
Transmitral flow velocity
Peak E velocity [cm/s] 64.1 ± 12.6 63.4 ± 12.0 0.822
Peak A velocity [cm/s] 61.5 ± 14.7 65.8 ± 17.4 0.285
E-DT [ms] 225.0 ± 23.5 214.9 ± 29.7 0.131
E/A 1.04 ± 0.3 0.96 ± 0.4 0.183
Mitral annular motion velocity
Peak Sm velocity [cm/s] 8.6 ± 1.3 7.6 ± 1.5 0.621
Peak Em velocity [cm/s] 10.2 ± 3.4 7.1 ± 2.4 0.004
Peak Am velocity [cm/s] 7.8 ± 3.2 9.2 ± 3.7 0.004
E/Em 6.3 ± 3.2 8.9 ± 1.7 0.001
Continuous numerical data were expressed as mean ± SD. Peak E velocity — peak early diastolic velocity of transmitral flow; Peak A velocity — peak
atrial systolic velocity of transmitral flow; E-DT — deceleration time from peak to baseline of the early diastolic transmitral flow velocity; E/A — the
ratio of E to A; Em — peak early diastolic mitral annular motion velocity; Am — peak atrial systolic mitral annular motion velocity; Sm — peak systolic
mitral annular motion velocity; E/Em — the ratio of E to Em; HF — heart failure
Table 3. Risk of heart failure associated with
elevated homocysteine.
Model Odds ratio (95% CI) P
Unadjusted 2.05 (1.50–2.50) 0.001
Model 1 1.15 (1.09–1.90) 0.034
Model 2 1.02 (1.06–1.93) 0.037
Model 3 1.27 (0.83–1.58) 0.456
Model 4 1.32 (1.02–1.62) 0.041
Model 1 — adjusted for male, smoking, body mass index, history of
hypertension, history of diabetes, LDL-cholesterol, and HDL-chole-
sterol; Model 2 — adjusted for Model 1 variables plus left ventricular
mass index, resting left ventricular ejection fraction and left ventricu-
lar end-diastolic volume index; Model 3 — adjusted for Model 2 va-
riables plus diastolic dysfunction (defined as impaired relaxation or
pseudonormal filling on echocardiography); Model 4 — adjusted for
Model 1 variables plus creatinine level; CI — confidence interval
Figure 1. Correlation between homocysteine concen-
trations and NYHA classification of heart failure.
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Overall, Hcy is an important HF quantification tool,
as well as an essential predictor of HF development
and evolution.
Some other studies have reported that in-
creased Hcy levels can promote endothelial dys-
function of coronary resistance vessels [18] with
increased oxidative stress. Hcy has also been pro-
ven to be involved in the induction of cardiac fibro-
sis, probably by activation of the transforming
growth factor-b1 [19] which is known to promote
myocardial damage.
Our results confirm the above studies and add
new evidence that the inverse correlation between
Hcy and LV function is independent of potential
confounders among individuals with previous MI.
The positive correlation between Hcy, BNP
and HF which we found, has been confirmed by oth-
er studies [20]. Previous data has shown that in
patients with elevated levels of Hcy, BNP is a sen-
sitive marker which highlights early HF [21], hav-
ing a high negative predictive value [22]. These
studies consider that high levels of Hcy are associ-
ated with an increase in the myocardial expression
of BNP, with the induction of LV remodeling. Al-
though elevated levels of BNP were not always as-
sociated with cardiac remodeling, BNP’s antifibrotic
and cytoprotective properties have been proved in
previous studies [23].
In our study, Hcy levels increased stepwise
with increasing NYHA class, revealing a significant
correlation between Hcy levels and NYHA class
severity of HF. Other studies have shown similar
outcomes. One recent investigation showed that an
increase in plasma Hcy levels has a stepwise asso-
ciation with the progression of NYHA class (con-
trols: 8.5 mmol/L, NYHA I: 10.3 mmol/L, NYHA II:
12.1 mmol/L, NYHA III: 13.5 mmol/L, NYHA IV:
17.4 mmol/L) [24].
The present study reports the cross-sectional
correlation of plasma Hcy with echocardiographic
LV parameters. Our data shows that LVEF values
were inversely correlated with Hcy levels. Howev-
er, a statistically significant correlation between
Hcy and commonly used markers of HF, such as
LVEF and NYHA class, was not established [25].
We found a strong correlation between plasma Hcy
and LV diastolic dysfunction, similar to the results
of the Framingham Heart Study [5].
The Physicians’ Health Study showed that
a moderate increase in plasma Hcy levels trebled
the relative risk for mortality from cardiovascular
disease and MI [26]. However, after further follow-
-up, this association proved not to be statistically
significant [27]. Elevated Hcy levels were indepen-
dently associated with the incidence of stroke, as
well as with cardiovascular disease and all-cause
mortality in the Framingham Heart Study [28].
However, such positive associations were not re-
ported in all studies. Folsom et al. [29] have dem-
onstrated in the ARIC study that adjustment for
other CHD risk factors cancelled the association of
incident CHD events with Hcy.
The prospective Caperhilly Study [30] differs
from our results, as it excludes high levels of Hcy
as a potential risk factor for acute coronary events
in a CHD-free middle-aged male population. Few
prospective epidemiological studies on subjects ini-
tially without CHD have shown similar findings.
A recent meta-analysis indicated that in healthy sub-
jects, Hcy levels are only weakly related to cardio-
vascular disease risk [31]. More recently, evidence
for an association between Hcy and the prevalence,
as well as the incidence, of HF has been postulat-
ed. Among patients with HF, elevated plasma Hcy
levels have been previously reported [20, 25]. More-
over, in a prospective study of 2,491 adults, Vasan
Table 4. Correlation of homocysteine (Hcy) level and severity of heart failure.
Patients with Hcy < 15 mmol/L Patients with Hcy > 15 mmol/L P
NYHA I 8 (27.5%) 5 (13.8%)
NYHA II 11 (37.9%) 14 (38.8%) 0.007
NYHA III–IV 10 (34.5%) 17 (47.2%)
LVEF (%) 39.2 (5.9%) 37.3 (5.7%) 0.023
LVMI [g/m2] 95.5 (13.2%) 102.9 (12.4%) 0.027
Mitral E/A ratio 1.0 (0.3%) 1.5 (0.1%) 0.002
Mitral E/Em ratio 7.8 (1.7%) 9.1 (1.9%) 0.043
BNP [ng/L] 356 (36.1%) 409 (38.4%) 0.031
Creatinine [mmol/L] 87 (0.19%) 98 (0.18%) 0.068
Continuous numerical data were expressed as mean (SD); LVEF — left ventricular ejection fraction; LVMI —  left ventricular mass index; Peak E velo-
city — peak early diastolic velocity of transmitral flow; Peak A velocity — peak atrial systolic velocity of transmitral flow; E/A — the ratio of E to A;
E/Em — the ratio of E to Em; BNP — brain natriuretic peptide
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et al. [4] demonstrated that the risk of HF during
an eight year follow-up was positively associated
with baseline Hcy concentration.
Our research did not show any significant cor-
relation between Hcy concentration in patients with
elevated plasma creatinine levels and the incidence
of HF. In other studies [32], Hcy levels in chronic
kidney disease patients were assessed and the in-
cidence of cardiovascular events was evaluated.
Plasma Hcy was not significantly correlated with
cardiovascular morbidity and mortality in patients
with moderate renal impairment. The effect of Hcy
on cardiovascular disease was not significant when
adjusted strictly to glomerular filtration rate.
Limitations of the study
We admit that the data from our study should
be validated by other reports. The first limitation
is the cross-sectional design itself, with case ascer-
tainment and time elapsed between the myocardial
event and the moment of study as possible bias
sources. Secondly, in some subsets, because of the
limited number of patients, we were unable to pro-
perly demonstrate a real correlation between Hcy
and HF. Further research is needed in order to es-
tablish a clinical protocol regarding the use of Hcy
levels in patients with HF.
Conclusions
Increased plasma Hcy levels independently cor-
relate with the severity of HF in patients with chronic
MI. We suggest that Hcy can be used in clinical prac-
tice as a valuable HF risk marker in patients with
chronic MI. However, present data is insufficient for
developing a clinical protocol. The cost of Hcy dos-
age prohibits its use at present, but if the prognostic
value of Hcy levels is confirmed by larger studies,
such an assessment could become cost-effective.
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